Cyclo Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- N. Scott Fine
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 6714 NW 16th Street Gainesville FL United States of America 32653
- IPO Date
- May 3, 2000
- CIK
- 0000922247
- Website
- cyclotherapeutics.com
- Similar Companies
- Business
- Cyclo Therapeutics, Inc. Cyclo Therapeutics, Inc. (NASDAQ: CYTH), a clinical-stage biotechnology company, develops cyclodextrin-based products for the treatment of neurodegenerative diseases; its lead product candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated in the United States and Europe, is in Phase III clinical trials for Niemann-Pick Disease Type C-1 (NPC1), a rare fatal genetic disorder characterized by cholesterol accumulation in lysosomes, and in Phase IIb clinical trials for Alzheimer's disease; the company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries primarily for use in diagnostics and specialty drugs. Founded in 1990 and headquartered in Gainesville, Florida, Cyclo Therapeutics, Inc. operates as a subsidiary of Rafael Holdings, Inc., with ongoing collaboration with the University of the Witwatersrand, Johannesburg, to advance the Trappsol Cyclo platform and explore pipeline expansion opportunities in additional indications. In recent major developments, the company completed a merger with Rafael Holdings, Inc. in March 2025 following shareholder approvals, enhancing its resources to advance the pivotal TransportNPC Phase 3 study with topline interim data expected mid-2025, after Rafael's prior investments including a March 2023 strategic funding, fall 2023 financing round, and 2024 convertible debt; earlier, it merged with Applied Molecular Transport in December 2023 and changed its name from CTD Holdings, Inc. in September 2019.
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, LTRPB, CYTH, SKGR on Behalf of Shareholders
Niemann-Pick Disease Pipeline Market Research 2024: Comprehensive Insights about 12+ Drugs Featuring Cyclo Therapeutics, Azafaros, IntraBio
Cyclo Therapeutics, Inc. (CYTH) Reports Q3 Loss, Lags Revenue Estimates
Shareholder Alert: Ademi LLP investigates whether Cyclo Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cyclo Therapeutics, Inc. - CYTH
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers of VGR, CYTH
Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Cyclo Therapeutics, Inc. (CYTH) Reports Q2 Loss, Misses Revenue Estimates
Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer's Disease from European Patent Office
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's Disease
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1
APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI